Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00880867
Other study ID # NVCI-0838
Secondary ID
Status Terminated
Phase Phase 1
First received April 10, 2009
Last updated July 19, 2011
Start date April 2009
Est. completion date April 2011

Study information

Verified date July 2011
Source Nevada Cancer Institute
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety of intratumoral Polyinosinicpolycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC)(Hiltonol®) in addition to low-dose local radiotherapy for adult patients with low grade lymphomas, including follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, and cutaneous T-cell lymphoma. The secondary endpoints are response rate, immune responses, and durability of responses as well as generation of antiinflammatory response at sites of tumor involvement.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date April 2011
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients must be at least 18 years of age.

2. Patients must have biopsy confirmed low-grade B-cell lymphoma (follicular, marginal zone, or small cell/chronic lymphocytic leukemia) or mycosis fungoides. B-cell lymphoma patients must have failed at least one prior therapy (chemotherapy or immunotherapy) or mycosis fungoides patients failed at least 1 topical or systemic treatment.

3. Patients must have at least one accessible tumor site that can be injected with poly-ICLC.

4. Patients must have measurable disease other than the injection site.

5. Patients must have a Karnofsky performance status of at least 70%.

6. Patients must have adequate hematologic, renal and liver function (i.e., absolute neutrophil count at least 1500/mm3, Platelets at least 100,000/mm3, creatinine no more than 1.7 mg/dl, total bilirubin no more than 1.5 mg/dl, transaminases no more than 4 times above the upper limits of the institutional normal).

7. Patients must be able to provide written informed consent.

8. Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. While animal testing has been negative, the anti-proliferative activity of this experimental drug may theoretically be harmful to the developing fetus or nursing infant.

9. Required washout period for prior therapy:

- Topical therapy: 2 weeks.

- Chemotherapy: 4 weeks

- Radiotherapy: (including phototherapy): 4 weeks 13 of 26

- Biological therapies: 4 weeks

- Other investigational therapy: 4 weeks

- Rituximab: 12 weeks

Exclusion Criteria:

1. Any history of autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, autoimmune hemolytic anemia, pure red cell aplasia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.

2. Off nucleoside or bendustine therapy for a minimum of 6 months

3. Prior treatment with Campath

4. Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active, prior treatment, or both).

5. Patients with active infection or with a fever > 38.5°C within three days prior to the first scheduled treatment.

6. CNS metastases.

7. Prior malignancy (active within 5 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix.

8. Current anticoagulant therapy (ASA no more than 325 mg/day allowed).

9. Significant cardiovascular disease (i.e., NYHA class 3 congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).

10. Pregnant or lactating.

11. Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with their participation in the study, or to interfere with the interpretation of the results.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Poly-ICLC
An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.

Locations

Country Name City State
United States Nevada Cancer Institute Las Vegas Nevada

Sponsors (2)

Lead Sponsor Collaborator
Nevada Cancer Institute CLL Topics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity (DLT) Days 1 through 4 during weeks 1, 2, 3, 4, and 8 Yes
Secondary Tumor Response Weeks 1 through 4, 8, 12, 16, and q3 months thereafter No
See also
  Status Clinical Trial Phase
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Withdrawn NCT02547948 - CD19-targeting CAR T Cells for B Cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03258047 - Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma Phase 2
Active, not recruiting NCT03478514 - Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Phase 2
Not yet recruiting NCT06058858 - Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Recruiting NCT06415708 - Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma Phase 2
Active, not recruiting NCT03307746 - A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma Phase 1/Phase 2
Terminated NCT03670888 - A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients Phase 1
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting NCT06213311 - A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma Phase 2
Recruiting NCT04008251 - Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies Phase 1
Recruiting NCT04637763 - CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Phase 1
Recruiting NCT04782193 - a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma Phase 1/Phase 2
Recruiting NCT03146533 - CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. Phase 1/Phase 2
Recruiting NCT05385263 - Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion Phase 2
Recruiting NCT03366324 - Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies Phase 1/Phase 2
Recruiting NCT03929107 - Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. Phase 2
Enrolling by invitation NCT05332054 - Long-Term Follow-up Study
Recruiting NCT04289220 - Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia Phase 1